Study on the effect of disease modifiers on pain, fatigue and quality of life in patients with NMOSD

Study on the effect of disease modifiers on pain, fatigue and quality of life (QOL) in patients with neuromyelitis optica spectrum disorder (NMOSD)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030210419

Enrollment

Registered

2021-11-10

Start date

2021-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica Spectrum Disorders NMOSD, Humanized monoclonal antibody, pain, fatigue, QOL

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.

Exclusion criteria

Exclusion criteria: Minors (under 20 years old)

Design outcomes

Primary

Measure	Time frame
Evaluation / measurement of motor function, ADL, disability, QOL, pain, fatigue, and depressive symptoms	—

Contacts

Public ContactIshii Kazuhiro

University of Tsukuba

kazishii@md.tsukuba.ac.jp+81-29-853-3204

Outcome results